The global market for Point-of-Care Glucose Testing was estimated at US$3.4 Billion in 2024 and is projected to reach US$4.1 Billion by 2030, growing at a CAGR of 3.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Point-of-Care Glucose Testing market.
The global rise in diabetes prevalence is one of the major factors driving the adoption of PoC glucose testing. According to the International Diabetes Federation (IDF), over 537 million adults worldwide have diabetes, and this number is expected to grow significantly in the coming years. Effective glucose monitoring and glycemic control are critical in preventing complications such as hypoglycemia, ketoacidosis, and cardiovascular diseases, making PoC glucose testing an integral part of routine diabetes care.
The increasing adoption of self-monitoring blood glucose (SMBG) devices and continuous glucose monitoring (CGM) systems has empowered diabetic patients to track their glucose levels frequently and make lifestyle or medication adjustments accordingly. Additionally, hospitals and emergency departments rely on PoC glucose meters for rapid hypoglycemia and hyperglycemia detection, ensuring immediate therapeutic interventions and improved patient outcomes.
One of the most significant innovations is the integration of wireless connectivity and digital health solutions. Modern PoC glucose meters are now equipped with Bluetooth, Wi-Fi, and mobile app compatibility, allowing seamless data transmission to electronic health records (EHRs), cloud-based platforms, and diabetes management applications. This feature enables remote patient monitoring (RPM) and physician-patient collaboration, making diabetes management more proactive and efficient.
Another breakthrough is the development of non-invasive and minimally invasive glucose monitoring devices. Traditional blood glucose testing requires finger-pricking, which can be painful and inconvenient for patients. Companies are now focusing on needle-free glucose monitoring using wearable biosensors, sweat-based glucose detection, and optical glucose sensors that utilize infrared light to measure glucose levels through the skin. Non-invasive glucose testing is expected to revolutionize diabetes management by enhancing patient adherence and improving user experience.
Advancements in continuous glucose monitoring (CGM) systems are also reshaping the market. Unlike traditional PoC glucose meters that provide single-time readings, CGMs offer real-time glucose monitoring with trend analysis and alerts for hypoglycemia or hyperglycemia. Leading manufacturers, such as Abbott (FreeStyle Libre), Dexcom (G6 and G7), and Medtronic (Guardian Connect), are continuously improving CGM technology to offer longer sensor wear, improved accuracy, and integration with insulin pumps.
Additionally, AI-driven glucose analytics and predictive algorithms are enhancing the precision of glucose monitoring. Machine learning models can now analyze glucose trends, predict fluctuations, and provide personalized recommendations for insulin dosing, meal planning, and physical activity adjustments. AI-powered PoC glucose testing solutions are expected to reduce complications, improve glycemic control, and support personalized diabetes management.
Global Point-of-Care Glucose Testing Market - Key Trends & Drivers Summarized
Why Is Point-of-Care Glucose Testing Essential in Diabetes Management?
Point-of-care (PoC) glucose testing plays a crucial role in diabetes management, emergency care, and critical care settings, providing immediate blood glucose readings that enable healthcare providers and patients to make real-time treatment decisions. Unlike traditional laboratory-based glucose tests, which require sample processing time, PoC glucose meters allow for rapid, on-the-spot glucose monitoring in hospitals, clinics, ambulatory settings, and even home environments.The global rise in diabetes prevalence is one of the major factors driving the adoption of PoC glucose testing. According to the International Diabetes Federation (IDF), over 537 million adults worldwide have diabetes, and this number is expected to grow significantly in the coming years. Effective glucose monitoring and glycemic control are critical in preventing complications such as hypoglycemia, ketoacidosis, and cardiovascular diseases, making PoC glucose testing an integral part of routine diabetes care.
The increasing adoption of self-monitoring blood glucose (SMBG) devices and continuous glucose monitoring (CGM) systems has empowered diabetic patients to track their glucose levels frequently and make lifestyle or medication adjustments accordingly. Additionally, hospitals and emergency departments rely on PoC glucose meters for rapid hypoglycemia and hyperglycemia detection, ensuring immediate therapeutic interventions and improved patient outcomes.
How Are Technological Advancements Improving PoC Glucose Testing?
The PoC glucose testing market is rapidly evolving with advancements in biosensor technology, connectivity solutions, and non-invasive glucose monitoring techniques.One of the most significant innovations is the integration of wireless connectivity and digital health solutions. Modern PoC glucose meters are now equipped with Bluetooth, Wi-Fi, and mobile app compatibility, allowing seamless data transmission to electronic health records (EHRs), cloud-based platforms, and diabetes management applications. This feature enables remote patient monitoring (RPM) and physician-patient collaboration, making diabetes management more proactive and efficient.
Another breakthrough is the development of non-invasive and minimally invasive glucose monitoring devices. Traditional blood glucose testing requires finger-pricking, which can be painful and inconvenient for patients. Companies are now focusing on needle-free glucose monitoring using wearable biosensors, sweat-based glucose detection, and optical glucose sensors that utilize infrared light to measure glucose levels through the skin. Non-invasive glucose testing is expected to revolutionize diabetes management by enhancing patient adherence and improving user experience.
Advancements in continuous glucose monitoring (CGM) systems are also reshaping the market. Unlike traditional PoC glucose meters that provide single-time readings, CGMs offer real-time glucose monitoring with trend analysis and alerts for hypoglycemia or hyperglycemia. Leading manufacturers, such as Abbott (FreeStyle Libre), Dexcom (G6 and G7), and Medtronic (Guardian Connect), are continuously improving CGM technology to offer longer sensor wear, improved accuracy, and integration with insulin pumps.
Additionally, AI-driven glucose analytics and predictive algorithms are enhancing the precision of glucose monitoring. Machine learning models can now analyze glucose trends, predict fluctuations, and provide personalized recommendations for insulin dosing, meal planning, and physical activity adjustments. AI-powered PoC glucose testing solutions are expected to reduce complications, improve glycemic control, and support personalized diabetes management.
Why Is Demand for PoC Glucose Testing Growing Across Healthcare and Homecare Settings?
The increasing prevalence of diabetes, metabolic disorders, and lifestyle-related diseases has led to the widespread adoption of PoC glucose testing in hospitals, outpatient clinics, and homecare settings.- Hospital & Critical Care Use: Healthcare facilities utilize PoC glucose testing for rapid diagnosis and management of acute glycemic events in intensive care units (ICUs), emergency rooms (ERs), and perioperative care. Patients undergoing surgery, trauma care, or chemotherapy often experience fluctuations in blood glucose levels, necessitating frequent bedside glucose monitoring to prevent complications.
- Self-Monitoring & Homecare: The demand for self-monitoring blood glucose (SMBG) devices has surged as more individuals manage diabetes independently at home. Compact, user-friendly glucose meters with easy-to-read displays, voice-assisted functions, and cloud-based tracking have made home-based glucose monitoring more convenient, particularly for elderly and visually impaired patients.
- Gestational Diabetes Monitoring: Pregnant women diagnosed with gestational diabetes mellitus (GDM) require frequent glucose monitoring to prevent complications for both the mother and baby. The adoption of portable, disposable, and wireless glucose meters in prenatal care is increasing to support early detection and management of GDM.
- Sports & Fitness Applications: Athletes and fitness enthusiasts are using PoC glucose testing and CGMs to monitor glucose variations before and after workouts. This trend has fueled demand for wearable glucose monitors that provide real-time insights into metabolic health and energy optimization.
What Factors Are Driving the Growth of the PoC Glucose Testing Market?
The growth in the PoC glucose testing market is driven by technological advancements, increasing diabetes prevalence, and rising consumer awareness about proactive healthcare.- Rising Diabetes Prevalence & Chronic Disease Burden: The global diabetes epidemic continues to fuel demand for real-time glucose monitoring solutions. Developing countries, particularly in Asia-Pacific, Latin America, and Africa, are experiencing a surge in diabetes cases, prompting governments to implement nationwide diabetes screening and prevention programs that incorporate PoC glucose testing.
- Government & Insurance Support for Diabetes Management: Many countries are expanding insurance coverage and reimbursement policies for glucose monitoring devices, making PoC glucose meters and CGMs more accessible to diabetic patients. Health agencies such as the FDA, EMA, and WHO are promoting the use of connected glucose meters and AI-driven diabetes management tools to improve healthcare outcomes.
- Increased Adoption of Wearable & Smart Glucose Monitoring Devices: The transition from traditional glucose meters to smart CGMs and biosensors is reshaping diabetes care. The demand for wearable CGMs with automated insulin delivery integration is growing, particularly among Type 1 and insulin-dependent Type 2 diabetic patients.
- Growing Demand for Minimally Invasive & Painless Testing Methods: Non-invasive glucose monitoring solutions are expected to gain traction as patients seek less painful, convenient, and continuous glucose tracking options. Research into tear, sweat, and saliva-based glucose detection is gaining momentum, with companies investing in next-generation non-invasive glucose sensors.
- Rise of AI & Data Analytics in Diabetes Care: AI-driven predictive analytics, glucose trend forecasting, and personalized diabetes coaching are transforming how patients and healthcare providers manage blood sugar levels. The integration of machine learning algorithms into PoC glucose testing devices is expected to optimize treatment decisions and reduce diabetes-related complications.
Scope of Study:
The report analyzes the Point-of-Care Glucose Testing market in terms of units by the following Segments, and Geographic Regions/Countries:- Segments: Product (Accu Check Aviva Meter, Onetouch Verio Flex, i-STAT, Bayer Contour Blood Glucose Monitoring System, Freestyle Lite, True Metrix, Accu-Chek Inform II, StatStrip, Others)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Accu Check Aviva Meter segment, which is expected to reach US$1.1 Billion by 2030 with a CAGR of a 4.1%. The Onetouch Verio Flex segment is also set to grow at 3.6% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $916.5 Million in 2024, and China, forecasted to grow at an impressive 6.4% CAGR to reach $819.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Point-of-Care Glucose Testing Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Point-of-Care Glucose Testing Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Point-of-Care Glucose Testing Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Laboratories, ACON Laboratories, Inc., ARKRAY, Inc., Ascensia Diabetes Care Holdings AG, Bayer AG and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 42 companies featured in this Point-of-Care Glucose Testing market report include:
- Abbott Laboratories
- ACON Laboratories, Inc.
- ARKRAY, Inc.
- Ascensia Diabetes Care Holdings AG
- Bayer AG
- Dexcom Inc.
- EKF Diagnostics Holdings plc
- F. Hoffmann-La Roche Ltd.
- iHealth Labs Inc.
- Insulet Corporation
- LifeScan Inc.
- Medtronic plc
- Nipro Corporation
- Nova Biomedical
- Prodigy Diabetes Care, LLC
- PTS Diagnostics
- Sanofi S.A.
- Terumo Corporation
- Trividia Health, Inc.
- Ypsomed Holding AG
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- ACON Laboratories, Inc.
- ARKRAY, Inc.
- Ascensia Diabetes Care Holdings AG
- Bayer AG
- Dexcom Inc.
- EKF Diagnostics Holdings plc
- F. Hoffmann-La Roche Ltd.
- iHealth Labs Inc.
- Insulet Corporation
- LifeScan Inc.
- Medtronic plc
- Nipro Corporation
- Nova Biomedical
- Prodigy Diabetes Care, LLC
- PTS Diagnostics
- Sanofi S.A.
- Terumo Corporation
- Trividia Health, Inc.
- Ypsomed Holding AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 72 |
| Published | June 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 3.4 Billion |
| Forecasted Market Value ( USD | $ 4.1 Billion |
| Compound Annual Growth Rate | 3.3% |
| Regions Covered | Global |
